132 related articles for article (PubMed ID: 8464045)
1. Synthesis and biological activities of angiotensin II, Sarilesin, and Sarmesin analogues containing Aze or Pip at position 7.
Matsoukas JM; Agelis G; Hondrelis J; Yamdagni R; Wu Q; Ganter R; Smith JR; Moore D; Moore GJ
J Med Chem; 1993 Apr; 36(7):904-11. PubMed ID: 8464045
[TBL] [Abstract][Full Text] [Related]
2. Differences in backbone structure between angiotensin II agonists and type I antagonists.
Matsoukas JM; Agelis G; Wahhab A; Hondrelis J; Panagiotopoulos D; Yamdagni R; Wu Q; Mavromoustakos T; Maia HL; Ganter R
J Med Chem; 1995 Nov; 38(23):4660-9. PubMed ID: 7473593
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for the competitive angiotensin antagonist [sarcosine,O-methyltyrosine4]angiotensin II (sarmesin).
Goghari MH; Franklin KJ; Moore GJ
J Med Chem; 1986 Jun; 29(6):1121-4. PubMed ID: 3754902
[TBL] [Abstract][Full Text] [Related]
4. Importance of the N-terminal domain of the type II angiotensin antagonist sarmesin for receptor blockade.
Matsoukas J; Cordopatis P; Belte U; Goghari MH; Ganter RC; Franklin KJ; Moore GJ
J Med Chem; 1988 Jul; 31(7):1418-21. PubMed ID: 2455051
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological activities of angiotensin II and Sarmesin analogues containing cyclohexylalanine.
Hondrelis J; Matsoukas J; Cordopatis P; Ganter RC; Franklin KJ; Moore GJ
Int J Pept Protein Res; 1991 Jan; 37(1):21-6. PubMed ID: 2045217
[TBL] [Abstract][Full Text] [Related]
6. Importance of the N-terminal domain of the type I angiotension II antagonist [Sar1,Ile8]ANG II for receptor blockade.
Moore GJ; Ganter RC; Goghari MH; Franklin KJ
Int J Pept Protein Res; 1991 Jul; 38(1):1-7. PubMed ID: 1938100
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activities of analogues of angiotensins II and III containing O-methyltyrosine and D-tryptophan.
Matsoukas JM; Goghari MH; Scanlon MN; Franklin KJ; Moore GJ
J Med Chem; 1985 Jun; 28(6):780-3. PubMed ID: 4009600
[TBL] [Abstract][Full Text] [Related]
8. 1H-NMR studies of sarmesin and [des1]sarmesin conformation in dimethylsulfoxide by nuclear Overhauser effect (NOE) enhancement spectroscopy: folding of the N- and C-terminal domains.
Matsoukas JM; Yamdagni R; Moore GJ
Peptides; 1990; 11(2):367-74. PubMed ID: 2356160
[TBL] [Abstract][Full Text] [Related]
9. Structural comparison between type I and type II antagonists: possible implications in the drug design of AT1 antagonists.
Roumelioti P; Tselios T; Alexopoulos K; Mavromoustakos T; Kolocouris A; Moore GJ; Matsoukas JM
Bioorg Med Chem Lett; 2000 Apr; 10(8):755-8. PubMed ID: 10782679
[TBL] [Abstract][Full Text] [Related]
10. An investigation of angiotensin II agonist and antagonist analogues with 5,5-dimethylthiazolidine-4-carboxylic acid and other constrained amino acids.
Samanen J; Cash T; Narindray D; Brandeis E; Adams W; Weideman H; Yellin T; Regoli D
J Med Chem; 1991 Oct; 34(10):3036-43. PubMed ID: 1920354
[TBL] [Abstract][Full Text] [Related]
11. Receptor interactions of the position 4 side chains of angiotensin II analogues: importance of aromatic ring quadrupole.
Moore GJ; Ganter RC; Matsoukas JM; Hondrelis J; Agelis G; Barlos K; Wilkinson S; Sandall J; Fowler P
J Mol Recognit; 1994 Dec; 7(4):251-6. PubMed ID: 7734150
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for the carboxy-terminus truncated analogues of angiotension II, a new class of angiotensin II antagonists.
Bovy PR; O'Neal JM; Olins GM; Patton DR; McMahon EG; Palomo M; Koepke JP; Salles KS; Trapani AJ; Smits GJ
J Med Chem; 1990 May; 33(5):1477-82. PubMed ID: 2329570
[TBL] [Abstract][Full Text] [Related]
13. Topographic probes of angiotensin and receptor: potent angiotensin II agonist containing diphenylalanine and long-acting antagonists containing biphenylalanine and 2-indan amino acid in position 8.
Hsieh KH; LaHann TR; Speth RC
J Med Chem; 1989 Apr; 32(4):898-903. PubMed ID: 2704034
[TBL] [Abstract][Full Text] [Related]
14. Structure-desensitization relationships of angiotensin analogues in the rat isolated uterus.
Moore GJ; Franklin KJ; Nystrom DM; Goghari MH
Can J Physiol Pharmacol; 1985 Aug; 63(8):966-71. PubMed ID: 4075269
[TBL] [Abstract][Full Text] [Related]
15. 1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): clustering of the aromatic rings in dimethylsulfoxide.
Matsoukas JM; Bigam G; Zhou N; Moore GJ
Peptides; 1990; 11(2):359-66. PubMed ID: 2356159
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a specific binding site for angiotensin II in chicken liver.
Bouley R; Gosselin M; Plante H; Servant G; Pérodin J; Arcand M; Guillemette G; Escher E
Can J Physiol Pharmacol; 1997 Jun; 75(6):568-75. PubMed ID: 9276130
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II analogues with sulphur-containing side-chains in position 5. A structure-activity relationship study.
Pérodin J; Bouley R; Escher E; Assimomytis N; Magafa V; Manessi-Zoupa E; Theodoropoulos D; Cordopatis P
Arzneimittelforschung; 2000 Jun; 50(6):526-9. PubMed ID: 10918944
[TBL] [Abstract][Full Text] [Related]
18. Novel synthesis of cyclic amide-linked analogues of angiotensins II and III.
Matsoukas JM; Hondrelis J; Agelis G; Barlos K; Gatos D; Ganter R; Moore D; Moore GJ
J Med Chem; 1994 Sep; 37(18):2958-69. PubMed ID: 8071943
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of angiotensin II antagonists containing sarcosine in position 7.
Moore GJ; Oudeman EM; Ko D; Nystrom DM
J Med Chem; 1979 Sep; 22(9):1147-9. PubMed ID: 490564
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of angiotensin II antagonists containing N- and O-methylated and other amino acid residues.
Khosla MC; Mũnoz-Ramírez H; Hall MM; Smeby RR; Khairallah PA; Bumpus FM; Peach MJ
J Med Chem; 1976 Feb; 19(2):244-50. PubMed ID: 2777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
